"I'm excited to announce the addition of Fera's ophthalmic ointment and solution products to Perrigo's Rx portfolio," Perrigo chairman and chief executive officer Joseph Papa stated. "The ophthalmic category has been one of high strategic interest to Perrigo as we continue to pursue opportunities that strengthen our leadership position within the niche Rx extended topical space. The breadth of the Fera portfolio allows us to become immediately relevant to patients and physicians across the country seeking cost-effective alternatives for the treatment of common ocular conditions."